NorthWest Biotherapeutics Inc (NWBO)

[antihama]

Oh Boy! Wow and Double Wow! "This is the big one!...You hear that, Elizabeth!"

LTBK-02 - Phase III Clinical Trial to Test the Safety and Efficacy of Autologous Tumor Lysate-Loaded Dendritic Cells in Patients with Newly Diagnosed Glioblastoma
Friday, November 20, 2020
Live Abstract Presenter(s)
Linda Liau, MD, PhD photo
Linda Liau, MD, PhD

Director, Brain Tumor Program, UCLA David Geffen School of Medicine
University of California Los Angeles

Arbor Pharmaceuticals (Consultant)JW Creagene (Consultant)

Author(s)
MB
Marnix Bosch, MBA, PhD

Northwest Biotherapeutics

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Participants should be aware of the following financial/non-financial relationships:
Linda M. Liau, MD, PhD: Arbor Pharmaceuticals (Consultant)JW Creagene (Consultant)
Marnix Bosch, MBA, PhD: No disclosure data submitted.


Background: Glioblastoma (GBM) is an incurable form of brain cancer with a high mortality rate in which multiple treatment attempts over the past decade have proven unsuccessful at extending survival. Early stage data have suggested that immunization against tumor cell antigens may be effective in GBM. In this Phase 3 study we aimed to assess whether autologous dendritic cells (DCs) loaded with autologous tumor cell lysate, is able to improve survival in these patients.